Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WHO Raises Doubts About India’s Wyeth Pneumonia Vaccinations

This article was originally published in PharmAsia News

Executive Summary

The pneumococcal conjugate vaccine India decided recently to add to its national immunization program apparently has no effect on the disease, according to the World Health Organization. A WHO bulletin said the PCV not only does not fight pneumonia, it actually increases asthma risks in children. A high-level committee of experts in India's Health Ministry earlier recommended including PCV in the immunization program and the ministry said it would do so within a year despite its high cost of more than $90 per child. The WHO bulletin advised governments to assess the cost of the Wyeth drug given its questionable effect, but Wyeth said the bulletin item contained inaccuracies and misleading statements. (Click here for more

You may also be interested in...



US Appropriators Seek FDA Reports On ‘Toxic’ Cosmetic Chemicals, ‘Natural’ Cosmetics

The FDA must report to the House Appropriations Committee on any work toward defining “natural” cosmetics and on the health effects of talc, asbestos and lead in cosmetic products. The committee’s 2021 FDA spending bill report also cites concerns about skin-lightening products containing “dangerous levels of mercury and hydroquinone.”

Verrica’s Molluscum Product Set Back By FDA Usage Questions

Verrica got a complete response rather than approval for its drug/device combo for molluscum, but says the FDA only needs additional information on product changes for safe usage by clinicians.

COVID-19 Consumer Health Market: Germ-Blocking Nasal Spray, 99.99% Effective Sanitizer, ‘Mask’ To Moisturize Hands

Sensory Cloud’s small study showed FEND nasal solution cut by 99% exhalation of bioaerosol to block COVID-19. Global BioProtect’s hand sanitizer with proprietary antibacterial technology eliminates 45 bacteria, fungi and virus. Trilogy Labs’  solution replenishes moisture in hands irritated by sanitizers.

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel